Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT115
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
BNT115 is an investigational **mRNA cancer vaccine** from BioNTech developed within the company's FixVac platform for solid tumors including ovarian cancer. It is a **nucleic acid vaccine** formulated as an RNA-lipoplex designed to deliver mRNA encoding a fixed set of shared, non-mutated tumor antigens to dendritic cells, with the goal of inducing coordinated innate and adaptive antitumor immune responses against cancer cells expressing those antigens. Publicly available information indicates that the program was not approved and its highest reported global development status is discontinued.
- Other names
- liposome-encapsulated TAAs mRNA vaccine W_ova1
02
Targets
MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on BNT115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT115.